Cargando…

Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden

Background. Doxorubicin/ifosfamide is a first-line systemic chemotherapy for the majority of advanced soft tissue sarcoma (ASTS) subtypes. Trabectedin is indicated for the treatment of ASTS after failure of anthracyclines and/or ifosfamide; however it is being increasingly used off-label as a first-...

Descripción completa

Detalles Bibliográficos
Autores principales: Guest, Julian F., Panca, Monica, Sladkevicius, Erikas, Gough, Nicholas, Linch, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835776/
https://www.ncbi.nlm.nih.gov/pubmed/24302852
http://dx.doi.org/10.1155/2013/725305
_version_ 1782292203701272576
author Guest, Julian F.
Panca, Monica
Sladkevicius, Erikas
Gough, Nicholas
Linch, Mark
author_facet Guest, Julian F.
Panca, Monica
Sladkevicius, Erikas
Gough, Nicholas
Linch, Mark
author_sort Guest, Julian F.
collection PubMed
description Background. Doxorubicin/ifosfamide is a first-line systemic chemotherapy for the majority of advanced soft tissue sarcoma (ASTS) subtypes. Trabectedin is indicated for the treatment of ASTS after failure of anthracyclines and/or ifosfamide; however it is being increasingly used off-label as a first-line treatment. This study estimated the cost effectiveness of these two treatments in the first-line management of ASTS in Italy, Spain, and Sweden. Methods. A Markov model was constructed to estimate the cost effectiveness of doxorubicin/ifosfamide compared to trabectedin monotherapy, defined as the cost per QALY gained, in each country. Results. First-line treatment with doxorubicin/ifosfamide resulted in lower two-year healthcare costs and more QALYs than first-line treatment with trabectedin monotherapy in all three countries. Probabilistic sensitivity analysis showed that at a cost per QALY threshold of €35,000, >90% of a cohort would be cost effectively treated with doxorubicin/ifosfamide compared to trabectedin monotherapy in all three countries. Conclusion. Within the model's limitations, first-line treatment of patients with ASTS with doxorubicin/ifosfamide instead of trabectedin monotherapy affords a cost-effective use of publicly funded healthcare resources in Italy, Spain, and Sweden and is therefore the preferred treatment in all three countries. These findings support the recommendation that trabectedin should remain a second-line treatment.
format Online
Article
Text
id pubmed-3835776
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-38357762013-12-03 Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden Guest, Julian F. Panca, Monica Sladkevicius, Erikas Gough, Nicholas Linch, Mark Sarcoma Research Article Background. Doxorubicin/ifosfamide is a first-line systemic chemotherapy for the majority of advanced soft tissue sarcoma (ASTS) subtypes. Trabectedin is indicated for the treatment of ASTS after failure of anthracyclines and/or ifosfamide; however it is being increasingly used off-label as a first-line treatment. This study estimated the cost effectiveness of these two treatments in the first-line management of ASTS in Italy, Spain, and Sweden. Methods. A Markov model was constructed to estimate the cost effectiveness of doxorubicin/ifosfamide compared to trabectedin monotherapy, defined as the cost per QALY gained, in each country. Results. First-line treatment with doxorubicin/ifosfamide resulted in lower two-year healthcare costs and more QALYs than first-line treatment with trabectedin monotherapy in all three countries. Probabilistic sensitivity analysis showed that at a cost per QALY threshold of €35,000, >90% of a cohort would be cost effectively treated with doxorubicin/ifosfamide compared to trabectedin monotherapy in all three countries. Conclusion. Within the model's limitations, first-line treatment of patients with ASTS with doxorubicin/ifosfamide instead of trabectedin monotherapy affords a cost-effective use of publicly funded healthcare resources in Italy, Spain, and Sweden and is therefore the preferred treatment in all three countries. These findings support the recommendation that trabectedin should remain a second-line treatment. Hindawi Publishing Corporation 2013 2013-11-03 /pmc/articles/PMC3835776/ /pubmed/24302852 http://dx.doi.org/10.1155/2013/725305 Text en Copyright © 2013 Julian F. Guest et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Guest, Julian F.
Panca, Monica
Sladkevicius, Erikas
Gough, Nicholas
Linch, Mark
Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden
title Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden
title_full Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden
title_fullStr Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden
title_full_unstemmed Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden
title_short Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden
title_sort cost effectiveness of first-line treatment with doxorubicin/ifosfamide compared to trabectedin monotherapy in the management of advanced soft tissue sarcoma in italy, spain, and sweden
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835776/
https://www.ncbi.nlm.nih.gov/pubmed/24302852
http://dx.doi.org/10.1155/2013/725305
work_keys_str_mv AT guestjulianf costeffectivenessoffirstlinetreatmentwithdoxorubicinifosfamidecomparedtotrabectedinmonotherapyinthemanagementofadvancedsofttissuesarcomainitalyspainandsweden
AT pancamonica costeffectivenessoffirstlinetreatmentwithdoxorubicinifosfamidecomparedtotrabectedinmonotherapyinthemanagementofadvancedsofttissuesarcomainitalyspainandsweden
AT sladkeviciuserikas costeffectivenessoffirstlinetreatmentwithdoxorubicinifosfamidecomparedtotrabectedinmonotherapyinthemanagementofadvancedsofttissuesarcomainitalyspainandsweden
AT goughnicholas costeffectivenessoffirstlinetreatmentwithdoxorubicinifosfamidecomparedtotrabectedinmonotherapyinthemanagementofadvancedsofttissuesarcomainitalyspainandsweden
AT linchmark costeffectivenessoffirstlinetreatmentwithdoxorubicinifosfamidecomparedtotrabectedinmonotherapyinthemanagementofadvancedsofttissuesarcomainitalyspainandsweden